Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Fasedienol by VistaGen Therapeutics for Anxiety Disorders: Likelihood of Approval
Fasedienol is under clinical development by VistaGen Therapeutics and currently in Phase III for Anxiety Disorders. According to GlobalData, Phase...
Data Insights
Fasedienol by VistaGen Therapeutics for Social Anxiety Disorder (SAD/Social Phobia): Likelihood of Approval
Fasedienol is under clinical development by VistaGen Therapeutics and currently in Phase III for Social Anxiety Disorder (SAD/Social Phobia). According...